Market Estimates
Valuation Metrics
Financials
Trading Trends
VTGN News & Events
Events Timeline

No data
News
People Also Watch
Frequently Asked Questions
What is Vistagen Therapeutics Inc (VTGN) stock price today?
The current price of VTGN is 0.6601 USD — it has decreased -6.25 % in the last trading day.
What is Vistagen Therapeutics Inc (VTGN)'s business?
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
What is the price predicton of VTGN Stock?
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 15.50 USD with a low forecast of 12.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
What is Vistagen Therapeutics Inc (VTGN)'s revenue for the last quarter?
Vistagen Therapeutics Inc revenue for the last quarter amounts to 258.00K USD, increased 40.98 % YoY.
What is Vistagen Therapeutics Inc (VTGN)'s earnings per share (EPS) for the last quarter?
Vistagen Therapeutics Inc. EPS for the last quarter amounts to -0.54 USD, increased 28.57 % YoY.
What changes have occurred in the market's expectations for Vistagen Therapeutics Inc (VTGN)'s fundamentals?
How many employees does Vistagen Therapeutics Inc (VTGN). have?
Vistagen Therapeutics Inc (VTGN) has 56 emplpoyees as of January 10 2026.
What is Vistagen Therapeutics Inc (VTGN) market cap?
Today VTGN has the market capitalization of 26.07M USD.



![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F041b67d80cb8438662c832f00f8adba3866d3e9c6da094a28ae30925ce6dc596.png&w=384&q=75)
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F453e839301842994cfcf9d27e57fd7e713232a1a2fb16ae0ea404c1c75a8f775.png&w=384&q=75)
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F93c8d0ec45cf2b5b1bc991be5b532e6c9aeffc6e4d0646599aba66414a766e35.png&w=384&q=75)